XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue by Product
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Revenue by Product Revenue by Product 
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the Chief Executive Officer (the “CEO”). The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products were included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 

On June 30, 2020, we sold the Hospital Products. See Note 3: Disposition of the Hospital Products. The following table presents a summary of total product sales by these products for the nine months ended September 30, 2020. The Company had no revenue during the three and nine months ended September 30, 2021 and the three months ended September 30, 2020: 
Nine Months Ended September 30,
Product Sales by Product:2020
Bloxiverz$2,201 
Vazculep10,429 
Akovaz9,545 
Other159 
Total product sales$22,334